Answers are grounded in this paper and cite their sources.
Streptozotocin was administered to 106 patients with advanced malignancies. Therapeutic responses were observed in Hodgkin's disease, 7/16, lymphocytic lymphoma, 3/11, Burkitt's lymphoma, 1/12, and acute lymphocytic leukemia, 1/5. Two of 7 patients with islet cell carcinoma, 1 insulin-secreting and 1 serotonin-secreting, responded, but 8 patients with malignant carcinoid tumors originating from the ileum failed to demonstrate a reduction in either urinary 5-hydroxyindole acetic acid or tumor mass. Additional evidence of drug activity was observed in 2 patients with melanoma and 1 of 8 cases with sarcoma. There was no apparent cross resistance between Streptozotocin, a methyl nitrosourea, and BCNU, a chloroethyl nitrosourea. Hematologic toxicity was observed in 9% of cases, whereas renal damage demonstrated in 28% was the principal treatment-limiting drug effect. Ten to twenty percent of each total dose is excreted in the urine with an intact N-nitroso group within 2 hours after administration. Recommended maximum doses based on results of these studies are 500 mg/m2 for 5 days or 1.5 g/m2/week in patients with normal renal function.
No takes yet. Share an insight, caveat, or question.
Schein et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: